Gunnar Aus
Carlanderska Sjukhuset · 134 works · 18,251 citations · h-index 45
Top works
- Screening and Prostate-Cancer Mortality in a Randomized European Study
- EAU Guidelines on Prostate Cancer
- Prostate-Cancer Mortality at 11 Years of Follow-up
- Mortality results from the Göteborg randomised population-based prostate-cancer screening trial
- Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up
- Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
- Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes
- Long-term Survival and Mortality in Prostate Cancer Treated with Noncurative Intent
- Infection after transrectal core biopsies of the prostate
- Outcomes of Men with Screen-Detected Prostate Cancer Eligible for Active Surveillance Who Were Managed Expectantly
- Transrectal Ultrasound Examination of the Prostate: Complications and Acceptance by Patients
- Prostate Cancer Mortality Reduction by Prostate-Specific Antigen–Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)
- Prostate cancer
- Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized Controlled Trial
- CHARACTERISTICS OF SCREENING DETECTED PROSTATE CANCER IN MEN 50 TO 66 YEARS OLD WITH 3 TO 4 NG./ML. PROSTATE SPECIFIC ANTIGEN
- Results of a randomized, population‐based study of biennial screening using serum prostate‐specific antigen measurement to detect prostate carcinoma
- Would prostate cancer detected by screening withprostate‐specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population‐based studies in Sweden
- Individualized Screening Interval for Prostate Cancer Based on Prostate-Specific Antigen Level
- Three‐month neoadjuvant hormonal therapy before radical prostatectomy: a 7‐year follow‐up of a randomized controlled trial
- EAU Guidelines on Prostate Cancer